drugset
Drugs / PRO 2000/5
last change Sep 2008 re-read 3 minutes ago

PRO 2000/5

also known as PRO 2000/5 Gel
Developed for
HIV infectious disease
Investigated by
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · HIV Prevention Trials Network · National Institute of Allergy and Infectious Diseases (NIAID) · National Institute of Mental Health (NIMH) · National Institute on Drug Abuse (NIDA)

Trials 1

today NCT00074425 · Ph 2
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00074425 Jan 2005 → Sep 2008 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed Missed primary

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as PRO 2000/5 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00074425 ↗
Known as PRO 2000/5 Gel “Phase II/IIb Safety and Effectiveness Study of the Vaginal Microbicides BufferGel and 0.5% PRO 2000/5 Gel (P) for the Prevention of HIV Infection in Women” NCT00074425 ↗
Action Inhibit “PRO 2000/5 inhibits viral entry into susceptible cells.” NCT00074425 ↗
Route Other “apply one dose of PRO 2000/5 Gel intravaginally” NCT00074425 ↗